Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Receivables (2016 - 2026)

Pharma-Bio Serv filings provide 17 years of Receivables readings, the most recent being $2.7 million for Q1 2026.

  • On a quarterly basis, Receivables fell 49.91% to $2.7 million in Q1 2026 year-over-year; TTM through Jan 2026 was $2.7 million, a 49.91% decrease, with the full-year FY2025 number at $5.3 million, up 111.08% from a year prior.
  • Receivables hit $2.7 million in Q1 2026 for Pharma-Bio Serv, up from $2.4 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $5.5 million in Q2 2022 to a low of $2.0 million in Q3 2025.
  • Median Receivables over the past 5 years was $4.8 million (2022), compared with a mean of $4.2 million.
  • Biggest five-year swings in Receivables: surged 771.07% in 2022 and later tumbled 61.97% in 2025.
  • Pharma-Bio Serv's Receivables stood at $5.0 million in 2022, then fell by 20.91% to $3.9 million in 2023, then plummeted by 36.29% to $2.5 million in 2024, then fell by 5.98% to $2.4 million in 2025, then increased by 12.45% to $2.7 million in 2026.
  • The last three reported values for Receivables were $2.7 million (Q1 2026), $2.4 million (Q4 2025), and $2.0 million (Q3 2025) per Business Quant data.